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Abstract
Background. Kidney transplantation is associated with harmful processes affecting the viability of the graft. One of these
processes is associated with the phenomenon of ischaemia–reperfusion injury. Anaesthetic conditioning is a widely
described strategy to attenuate ischaemia–reperfusion injury. We therefore conducted the Volatile Anaesthetic Protection of
Renal Transplants-1 trial, a pilot project evaluating the influence of two anaesthetic regimens, propofol- vs sevoflurane-
based anaesthesia, on biochemical and clinical outcomes in living donor kidney transplantation.
Methods. Sixty couples were randomly assigned to the following three groups: PROP (donor and recipient propofol), SEVO
(donor and recipient sevoflurane), and PROSE (donor propofol and recipient sevoflurane). The primary outcome was renal
injury reflected by urinary biomarkers. The follow-up period was 2 yr.
Results. Three couples were excluded, leaving 57 couples for analysis. Concentrations of kidney injury molecule-1 (KIM-1),
N-acetyl-b-D-glucosaminidase (NAG), and heart-type fatty acid binding protein (H-FABP) in the first urine upon reperfusion
showed no differences. On day 2, KIM-1 concentrations were higher in SEVO [952.8 (interquartile range 311.8–1893.0) pg
mmol1] compared with PROP [301.2 (202.0–504.7) pg mmol1]. This was the same for NAG: SEVO, 1.835 (1.162–2.457) IU
mmol1 vs PROP, 1.078 (0.819–1.713) IU mmol1. Concentrations of H-FABP showed no differences. Measured glomerular fil-
tration rate at 3, 6, and 12 months showed no difference. After 2 yr, there was a difference in the acute rejection rate
(P¼0.039). Post hoc testing revealed a difference between PROP (35%) and PROSE (5%; P¼0.020). The difference between PROP
and SEVO (11%) was not significant (P¼0.110).
Conclusions. The SEVO group showed higher urinary KIM-1 and NAG concentrations in living donor kidney transplantation
on the second day after transplantation. This was not reflected in inferior graft outcome.
Clinical trial registration. NCT01248871.
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Clinical Practice
Anaesthetic conditioning (AC) is the ability of anaesthetic
agents to induce biochemical changes that may attenuate
ischaemia–reperfusion injury (IRI).1 These capacities are attrib-
uted in particular to volatile anaesthetic (VA) agents, such as
sevoflurane or isoflurane, and to a much lesser extent to propo-
fol. Depending on the timing of administration, it is defined as
preconditioning (before ischaemia), perconditioning (during
ischaemia), or postconditioning (directly upon reperfusion).
Protective effects of AC of VA on the heart are demonstrated
in vitro, in animal species, and in randomized controlled clinical
trials.2–4 In contrast, in kidneys the evidence for AC of VA is
restricted to in vitro and animal work. Rats anaesthetized with
VA and subjected to renal IRI showed reduced concentrations of
plasma creatinine and cytokines, reduced pro-inflammatory
leucocyte infiltration, and reduced histological renal necrosis
compared with rats anaesthetized with pentobarbital or ket-
amine.5 In mice, anaesthesia with isoflurane led to reductions
of neutrophil, macrophage, and lymphocyte infiltration after
renal IRI compared with pentobarbital anaesthesia.6
The presumed mechanism of renal AC with VA is complex
and involves several pathways in different cell types.7 In renal
tubular cells, VA exposure will lead to translocation of phospha-
tidylserine (PS) to the outer leaflet of the plasma membrane.
This externalization of PS inflicts release of transforming
growth factor-b (TGF-b) in neighbouring cells via ligation of PS
receptors. Binding of TGF-b to the TGF-b receptor results in
increased expression of CD-73 via nuclear translocation of tran-
scription factor mothers against decapentaplegic homolog 3
(SMAD-3). This increased CD-73 expression increases adenosine
formation. Activation of adenosine receptor (AR) then results in
sphingosine kinase (SK-1) upregulation directly via hypoxic
inducible factor 1a (HIF-1a) signalling or indirectly via increased
interleukin (IL)-11 synthesis by activation of extracellular regu-
lated kinase/mitogen-activated protein kinase (ERK/MAPK). SK-
1 itself promotes sphinogosine-1-phosphate (S1P) synthesis.
Sphinogosine-1-phosphate signalling is associated with cell sur-
vival and cell growth by activation of the S1P receptor (S1PR).
Furthermore, in the immune system S1P is a regulator of T- and
B-cell trafficking and is directly able to suppress the Toll-like
receptor (TLR)-mediated immune response from T cells.7
Experiments on pulmonary epithelial and endothelial cells
suggest that the trifluoronated carbon groups of VA are responsi-
ble for the anti-inflammatory and immunomodulatory effects.8
To date, the choice of anaesthetic agent in renal transplanta-
tion is mainly based on the individual preference of the attend-
ing anaesthetist or based on local institutional protocols. Given
that IRI is inevitable in organ transplantation and AC might be
an effective way to reduce IRI, we designed the Volatile
Anaesthetic Protection Of Renal transplants (VAPOR) trial,
which is a two-step study looking at the effect of two commonly
used anaesthetic agents on renal outcome in kidney transplan-
tation. As the first step, we report here the results of the
VAPOR-1 trial, a pilot study in which propofol-based anaesthe-
sia was compared with sevoflurane-based anaesthesia in living
donor kidney transplantation (LDKT). We have chosen LDKT for
the first step because it is a homogeneous and reproducible
model of kidney transplantation. It provided us with a maxi-
mally controllable research setting, with optimal kidneys and
similar ischaemia times. Given that the rate of failure defined as
delayed graft function (DGF) is low (<5%) compared with renal
transplantation with kidneys from deceased brain death donor
(15–40%) or deceased circulatory death donor (40–80%), we con-
sidered VAPOR-1 a proof of concept.
We hypothesized that sevoflurane-based anaesthesia is able
to induce renal AC and thereby reduces post-transplant renal
injury reflected by lower concentrations of kidney injury bio-
markers compared with propofol-based anaesthesia.
Methods
Study design and population
This prospective, randomized controlled pilot project was con-
ducted at the University Medical Centre Groningen between
September 2010 and October 2014. The Institutional Review
Board approved the study protocol (METc 2009/334), which was
conducted in adherence to the Declaration of Helsinki, and reg-
istered with ClinicalTrials.gov: NCT01248871. Inclusion criteria
were as follows: age 18 yr, donation of the left kidney, and
written informed consent. Exclusion criteria were as follows:
ABO-incompatible transplantation, altruistic donors, and
BMI17 or  35 kg m2. Only left kidneys were included because
the gonadal vein was used for venous sampling upon reperfu-
sion. The follow-up period was 2 yr.
Sample size calculation
Owing to the lack of available data in this investigational area, it
was difficult to perform an adequate sample size calculation
based on published data. However, we did perform a sample size
calculation based on clinical urinary kidney injury molecule-1
(KIM-1) concentrations in living donors in our own centre
(Nijboer WN, Leuvenink HGD, Ploeg RJ. University Medical Centre
Groningen, unpublished data) to give us some idea of group size.
In a one-way ANOVA with suspected means of 100, 150, and
200 ng ml1 and a common SD within a group of 90 ng nl1, we
would have needed 17 patients per group (at a significance level
of 0.05 and a power of 80%). Based upon this calculation, we
decided to include 20 couples per group.
Randomization
Randomization was performed by the attending anaesthetist
using sealed envelopes. Sixty donor–recipient couples (120
patients in total) were equally assigned to one of the following
groups: PROP, propofol for donor and recipient, control group;
SEVO, sevoflurane for donor and recipient, anaesthetic pre- and
postconditioning; and PROSE, propofol for donor and
sevoflurane for recipient, anaesthetic postconditioning. Owing
to negative results in animal experiments, we did not include a
fourth group (SEPRO, sevoflurane for donor and propofol for
recipient, anaesthetic preconditioning).5
Editor’s key points
• Ischaemia reperfusion injury (IRI) may affect outcome after
several types of surgery including kidney transplantation
• Anaesthetic agents may attenuate IRI to varying degrees
through preconditioning, but the effect on outcome
after kidney transplantation is unknown
• In this randomized study, there were some differences in
early urinary biomarkers of kidney injury between patients
receiving Sevoflurane or propofol-based anaesthesia
• There were no significant differences in outcome
between groups, but the study may have been under-
powered to detect this
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Anaesthetic protocol
Anaesthesia was performed by two anaesthetists to reduce
inter-operator variability. Anaesthetic and haemodynamic
management were strictly protocollized. In PROP, anaesthesia
was induced and maintained with propofol, using target-
controlled infusion (pharmacokinetic–pharmacodynamic model
of Schnider and colleagues).9 In SEVO, anaesthesia was induced
with a manually administered propofol bolus and maintained
with sevoflurane. In PROSE, the donor was treated as for PROP
and the recipient as for SEVO. A bispectral index (BIS) monitor
was used to monitor anaesthetic depth. A value between 40 and
60 was considered adequate. In all groups, analgesia was man-
aged with remifentanil using a target-controlled infusion
system (pharmacokinetic–pharmacodynamic model of Minto
and colleagues).10 The initial target effect site concentration
(Cet) was set at 2 ng ml1. Neuromuscular block was accom-
plished with cisatracurium 0.2 mg kg1. In donors, arterial blood
pressure was monitored using a radial artery catheter. In recipi-
ents, advanced haemodynamic monitoring with PiCCOVR
(PULSION Medical Systems SE, Feldkirchen, Germany) was per-
formed. The goal was to maintain a mean arterial pressure
(MAP) within 80% of patient baseline measures. When hypoten-
sion occurred, the first step was to adjust the depth of anaesthe-
sia or analgesia. If that was insufficient or not possible, the
patient received one or more boluses of ephedrine (5 mg) or phe-
nylephrine (100 lg) (choice depending on heart rate). Fluid man-
agement in the donor encompassed 60 ml kg1 of crystalloids,
whereas in the recipient it was goal directed based on stroke
volume variation. The goal was set at a stroke volume variation
of<10% at the moment of reperfusion. Predominantly, Ringers’
lactate was used. If hyponatraemia occurred, Ringers’ lactate
was replaced by normal saline. Colloids were not given. Fluid
administration was on a continuous basis; fluid challenges were
not performed. After induction, donors received ceftazidine
1000 mg and recipients received solumedrol 40 mg, basiliximab
20 mg and cefuroxim 1500 mg i.v. Mannitol 20% 200 ml was
given before explanting the kidney from the donor and reperfu-
sion in the recipient. If patients were at risk for development of
postoperative nausea and vomiting (PONV), ondansetron 4 mg
was given. Postoperative nausea and vomiting in the post-
anaesthesia care unit (PACU) was treated with a step-up sched-
ule of ondansetron 4 mg, dexamethasone 5 mg, and droperidol
0.625 mg. Piritramide and paracetamol were used for postopera-
tive pain management.
Surgical technique
Kidney donation was performed via hand-assisted laparoscopy.
Thereafter, the kidney was flushed and perfused with cold
University of Wisconsin solution (ViaSpan, DuPont, Wilmington,
NC, USA or Belzer UWTM, Bridge to life, Columbia SC, USA) and
stored on ice. Transplantation was performed according to the
local standardized protocol. Before implantation, a small catheter
(5 Fr; Tyco Healthcare Ltd, Tullamore, Ireland) was inserted in the
gonadal vein. This catheter was used for venous sampling from
the transplanted kidney until 30 min post-reperfusion. An 8 or 6
Fr splint in the ureter was exteriorized as a suprapubic catheter
and removed routinely on day 10.
Immunosuppressive protocol
The immunosuppressive regimen comprised triple therapy con-
taining prednisolone, a calcineurin inhibitor, and mofetil
mycophenolate. The mofetil mycophenolate and first dose of
calcineurin inhibitor were given before surgery. After induction
of anaesthesia, basiliximab 20 mg and methylprednisolone
40 mg were given. A second dose of basiliximab 20 mg was given
on day 4. In the event of side-effects, ciclosporin was replaced
by tacrolimus or vice versa. Azathioprine was started in the
event of intolerance to mofetil mycophenolate.
Samples
Blood and urine samples were obtained at standardized time points
(Supplementary material, Table S1). In recipients, additional renal
venous samples were drawn via the gonadal vein catheter. These
were obtained simultaneously with systemic arterial samples at
30 s, 5, 10, and 30 min after reperfusion. Open needle biopsies from
the transplanted kidney were obtained before implantation and
30 min after reperfusion. Each biopsy was divided in two for
embedding in paraffin and storing in RNAlater. Sampling days 1, 2,
6, and 9 were chosen for logistic reasons.
Study end points
The primary outcome was renal injury reflected by the kidney
injury biomarkers KIM-1, N-acetyl-b-D-glucosaminidase (NAG),
and heart-type fatty acid binding protein (H-FABP) in splint urine.
Secondary biochemical end points were plasma markers reflect-
ing IRI and reduction of plasma creatinine concentrations in the
first 9 days. Biopsies were analysed for expression of caspase 3
(apoptosis), TLRs 2 and 4 (activation of innate immunity), heme
oxygenase-1 (HO-1), heat shock protein 70 (hsp70), C3 and C5AR
(complement activation), intercellular adhesion molecule-1
(ICAM-1), angiopoietin 2, and its receptor Tie2 (endothelial activa-
tion). Periodic acid–Schiff-stained biopsies were scored by a renal
pathologist for signs of glomerulitis, tubulitis, tubular atrophy,
acute tubular necrosis, interstitial and vascular lesions, and pre-
existing damage. Acute tubular necrosis scoring was performed
as described by Tavares and colleagues.11 This scoring system is
given in Supplementary material, Table S2. The pathology scor-
ing system is given in Supplementary material, Table S3.
Secondary clinical end points were as follows: DGF defined
as need for dialysis in the first week after transplantation; pri-
mary non-function (PNF) defined as permanent lack of function
of the allograft; measured glomerular filtration rate (mGFR) at 3,
6, and 12 months with use of 125I-iothalamate; length of hospital
stay; postoperative complications according to the Clavien–
Dindo classification;12 treated and biopsy-proven acute rejec-
tion (AR); and 2 yr graft and patient survival.
Sample measurements
Urinary KIM-1 and H-FABP concentrations were measured
by duoset enzyme-linked immunosorbent assay (ELISA; R&D
systems, Minneapolis, MN, USA). Urinary NAG activity was
measured by a modified enzyme assay using p-nitrophenyl-N-
acetyl-b-D-glucosaminide as substrate. Urinary creatinine was
determined on a Roche Modular chemistry analyser (Roche
Diagnostics, Indianapolis, IN, USA). Plasma concentrations of
cytokines were determined by multiplex ELISA (Ebioscience,
San Diego, CA, USA) and analysed using Luminex 100 equip-
ment (Linco, St Louis, MO, USA). Plasma concentrations of IL-6,
IL-8, and IL-10 were determined by human ELISA kits
(Ebioscience, San Diego, CA, USA). All analyses were according
to the manufacturers’ instructions.
Gene expression in kidney biopsies was measured as
described before.13 Studied genes, primer sequences, and ampli-
con size are given in Supplementary material, Table S4.
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Statistical analysis
For statistical analysis, SPSS version 22 (IBM Corp, Armonk, NY, USA)
and GraphPadPrsim (GraphPad software, Inc, La Jolla, CA, USA) ver-
sion 5.04 were used. Categorical data were analysed by v2 or Fisher’s
exact tests. Continuous data were tested for normality with the use
of the Shapiro–Wilk test. Values are given as the mean (SD) or median
with interquartile range (IQR). For normally distributed values, ANOVA
or Student’s unpaired t-tests were used. If variables were not
normally distributed, the Kruskal–Wallis or Mann–Whitney U-test
was applied. When differences between the three groups were
significant, Bonferroni post hoc testing was performed.
For the repeated measures on IL-6, IL-8, and IL-10, linear mixed
models were performed testing for possible interactions between
group and time. In these analyses, we used autoregression correla-
tion between the repeated measurements. This model has also
been tested for mGFR at 3, 6, and 12 months. Regarding differences
between IL concentrations in renal and systemic blood samples,
an area under the curve was calculated between 30 s and 30 min
after reperfusion. The Wilcoxon signed-rank test was applied to
test the differences between the renal and systemic samples.
Differences between cold storage and reperfusion biopsies were
tested with Student’s paired t-tests in the event of normally dis-
tributed differences or the Wilcoxon matched-pairs signed-rank
test otherwise. The Kaplan–Meier method was used to analyse
acute rejection episodes. Differences between the curves were
determined with the log-rank test. All reported P-values are two
sided. A P-value of 0.05 was considered significant. The attend-
ing anaesthetist was aware of the allocation. Patients, surgeons,
nephrologists, the pathologist, and laboratory analysts were
blinded to treatment allocation.
Results
From September 2010 until October 2012 (primary study comple-
tion date), 125 living donor kidney transplantations were per-
formed in the University Medical Centre Groningen, of which 88
involved donation of the left kidney. Of those 88, four donors
were altruistic donors, seven couples were ABO incompatible,
two recipients had a BMI <17.5 or >35.7 kg m2, seven patients
did not give informed consent, and eight couples could not par-
ticipate for logistic reasons (e.g. two transplantations on the
same day) or because of participation in another study.
Therefore, 60 couples were equally randomized to three groups.
In PROP, two couples were excluded because of surgical protocol
violations. Owing to surgical difficulties in the recipients, these
kidneys were exposed to extensively prolonged and additional
ischaemic episodes. In SEVO, one couple was excluded because
of violation of the immunosuppressive protocol, because after
surgery the recipient did not take any immunosuppressant for
several days. Therefore, 57 couples were eligible for sample anal-
ysis. One couple in PROP was lost to follow-up beause the recipi-
ent suffered a cardiac arrest on day 9. Resuscitation was started
but was unsuccessful. Post-mortem examination showed a retro-
peritoneal haematoma and pulmonary aspiration. In total, 56
couples were eligible for follow-up (Fig. 1, CONSORT diagram).
Patients
Table 1 summarizes the characteristics of donors and recipi-
ents. There were no differences between the three groups with
regard to relevant baseline characteristics.
Donors were all relatively healthy persons. The most common
co-morbidities were hypertension and hypercholesterolaemia.
We have combined these two in cardiovascular co-morbidity in
Table 1. None of the donors was suffering from diabetes.
Medications used were predominantly antihypertensive medica-
tions, such as b-blockers, calcium channel blockers, diuretics,
angiotensin converting enzyme inhibitor or angiotensine II recep-
tor antagonist, and statins. There were no differences between
groups in the use of these medications. Most recipients had multi-
ple co-morbidities and co-medications. Underlying kidney disease
and cardiovascular co-morbidity are listed in Table 1. With regard
to cardiovascular medications, the groups were comparable.
Intraoperative parameters and anaesthesia
Clinically relevant intra- and postoperative parameters are sum-
marized in Table 2. The duration of the procedures and warm
and cold ischaemia times were identical. Patients anaesthetized
with sevoflurane showed a higher average BIS value during the
procedure. In recipients, MAP, also reported as average MAP
during the procedure, was higher in PROP compared with SEVO
and PROSE. Haemodynamic profiles over time of MAP and stroke
volume variation are listed in Supplementary material, Figs S1–
S3. These profiles are comparable between groups. Patients
anaesthetized with sevoflurane more frequently received a bolus
of ephedrine compared with patients anaesthetized with propo-
fol. This occurred predominantly after induction of anaesthesia.
No extended hypotensive periods were observed, and none of
the patients received vasoactive medication on a continuous
basis. In all patients, remifentanil was started at 2 ng ml1 Cet. In
PROP recipients, average Cet of remifentanil during the procedure
was higher compared with SEVO and PROSE.
The intraoperative amount of fluid was comparable between
groups. Predominantly Ringer’s lactate was used. This was
replaced by one or two bags of saline (500–1000 ml) in the event
of hyponatraemia; this was required in eight donors (four PROP,
two SEVO, and two PROSE) and 19 recipients (seven PROP, six
SEVO, and six PROSE). No colloids were used. Urine production
in recipients occurred in all patients immediately upon
reperfusion.
Donors in SEVO more frequently received a prophylactic
dose of ondansetron. In recipients, the incidence of PONV at the
PACU was significantly higher in SEVO and PROSE groups, and
these patients were treated with ondansetron more frequently.
On the ward, there was no difference in the incidence of nausea
between groups.
Immunosuppressants
The immunosuppressive regimens on day 7 and at 3, 6, 12, and
24 months after transplantation are listed in Supplementary
material, Table S5. There were no differences between groups in
the types of immunosuppressants or the trough concentrations
of ciclosporin and tacrolimus at the different time points.
Urinary renal injury markers
The KIM-1, NAG, and H-FABP concentrations were measured in
splint urine (urine from the transplanted kidney) and corrected
for urinary creatinine concentrations to correct for volume dilu-
tion. Sample points were as follows: first urine produced upon
reperfusion, 2 h before surgery, and day 1, 2, 6 and 9 (Table S1
R6–R11). Individual concentrations per patient at different time
points are displayed per group in Fig. 2. Median (IQR) concen-
trations and per time point are listed in Table 3. Concentrations
of biomarkers in the first urine produced upon reperfusion were
comparable between groups. On day 2, KIM-1 concentrations
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were higher in SEVO compared with PROP (P¼0.033). PROSE
showed a tendency to a higher concentration of KIM-1 on day 2
compared with PROP (P¼0.071). On day 1, NAG activity was
lower in SEVO compared with PROP (P¼0.014) and PROSE
(P¼0.008). On day 2, NAG activity was higher in SEVO compared
with PROP (P¼0.018). Other time points and concentrations of H-
FABP showed no differences (Fig. 2).
Blood biomarkers
Cytokines were measured in plasma of the recipient. Time
points were as follows: induction of anaesthesia, start of sur-
gery, 30 s, 5, 10, and 30 min after reperfusion, 2 h postopera-
tive, and day 1 and 2. During reperfusion, venous renal and
systemic arterial samples were obtained simultaneously (30 s,
5, 10 and 30 min after reperfusion). Concentrations of IL-1b,
IL-4, IL-5, IL-9, IL-18, TNF-a, TGF-b, and interferon-c were
below the detection thresholds of our assays. Concentrations
of IL-6, IL-8, and IL-10 were measured. The change in plasma
concentrations over time did not differ between groups. Peak
concentrations of IL-8 were reached 30 min post-reperfusion
and of IL-6 and IL-10, respectively, 2 and 24 h after surgery.
Release of IL-6 from the kidney during reperfusion was signif-
icantly higher than systemic concentrations of IL-6 (P<0.001).
This was the found in all groups. Interluekin-8 and IL-10
showed no differences in renal and systemic concentrations
(P¼0.845 and P¼0.226, respectively; Supplementary material,
Fig. S4).
CONSORT flow diagram VAPOR 1 
Couples assessed for eligibility (n=125) 
Excluded  (n=65) 
♦ Not meeting inclusion criteria (n=50)
♦ Declined to participate (n=7)
♦ Other reasons (n=8)
Analysed (n=18) 
Excluded (n=2) because of





SEVO (n=20) PROSE (n=20)
Analysed (n=19)





Lost to follow-up 1
Patient died on day 9
Follow-up (n=19) Follow-up (n=20)
Randomized (n=60)
Fig 1 Consort diagram.
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Biopsy analysis
Gene expression in cold storage and reperfusion biopsies are
listed in Supplementary material, Table S6. Regarding the cold
biopsies, two groups were compared (PROP-PROSE vs SEVO)
because at that moment the kidney was exposed to either pro-
pofol or sevoflurane. There were no differences in gene expres-
sions with the exception of HO-1, which was higher in SEVO.
There were no differences in reperfusion biopsies between
groups. Hsp70 was upregulated in reperfusion biopsies in all
groups, and Tie2 was downregulated in PROP. Pathology scores
are listed in Supplementary material, Table S7. No signs of pre-
existing damage were observed, and biopsy scores did not differ
between groups. All biopsies showed signs of acute tubular
necrosis assessed by cytoplasmic changes or apoptosis of
the tubular epithelium. In cold storage biopsies, coalescent
groups of necrotic tubules were seen in the renal cortex. There
were more extensive areas of tubular necrosis in 66% of the
PROSE, 70% of the SEVO, and 90% of the PROP reperfusion
biopsies.
Medullar biopsies were excluded.
Creatinine reduction
Relative creatinine reduction from baseline for the first 9 days is dis-
played in Supplementary material, Table S8. The baseline was the
creatinine concentration on the morning of transplantation. There
were no differences between groups during the first 8 days. On day 9,
SEVO showed a greater reduction compared with PROP (P¼0.047).
Clinical end points
Clinical end points are listed in Table 4. Two patients in PROP
and one in SEVO experienced DGF. Two grafts were lost because
of rejection. There was no difference between groups in mGFR
at 3, 6, and 12 months. Over time there was a similar decline in
GFR, with an average decline of 0.6 ml min1 month1 (P<0.001).
Postoperative complications were comparable between groups.
One patient in PROP died on day 9 as described in the Methods.
Acute rejection
During a 2 yr follow-up, nine of 56 patients (16%) experienced acute
rejection (Table 4). All rejections were T-cell mediated, and donor-
Table 1 Baseline characteristics of donors and recipients. Groups are as follows: PROP (donor and recipient propofol), SEVO (donor and
recipient sevoflurane), and PROSE (donor propofol and recipient sevoflurane). Data are given as the mean (SD), median (interquartile
range), or n (%). HLA, human leucocyte antigen; MAP, mean arterial pressure; mGFR, glomerular filtration rate measured by isotope
125I-iothalamate; PRA panel specific antibodies 15%
PROP SEVO PROSE
Donors n518 n519 n520
Age (yr) 54 (19–64) 54 (38–76) 52 (38–69)
Male [n (%)] 8 (44) 9 (47) 9 (45)
BMI (kg m2) 26.1 (3.7) 27.4 (3.3) 27.1 (2.6)
ASA I/II 11/7 12/7 11/9
mGFR (ml min1) 113 (21) 116 (25) 119 (23)
Smoking [n (%)] 5 (27) 5 (26) 6 (30)
Cardiovascular co-morbidity [n (%)] 4 (22) 6 (32) 6 (30)
MAP baseline (mm Hg) 94 (93–105) 95 (85–105) 95 (86–103)
Recipients n518 n519 n520
Age (yr) 48.8 (15.4) 52.0 (11.5) 51.5 (10.4)
Male [n (%)] 11 (61) 8 (42) 8 (40)
BMI (kg m2) 26.1 (3.2) 25.2 (3.8) 24.8 (3.7)
ASA II/III 7/11 4/15 6/14
Underlying renal disease (n)
Diabetes 1 2 2
IgA nephropathy 3 0 3
Autoimmune 3 1 0
Glomerulonephritis 1 0 3
Vasculitis 0 1 2
Polycystic kidney disease 1 5 3
Renal atrophy 2 4 0
Sclerosis 3 2 2
Tubulointerstitial nephritis 1 1 3
Other 3 3 2
Cardiovascular co-morbidity [n (%)] 17 (94) 19 (100) 19 (95)
MAP baseline (mm Hg) 106 (11.1) 100 (15.3) 101 (11.5)
Unrelated donor [n (%)] 9 (50) 9 (47) 11 (55)
Pre-emptive transplantation [n (%)] 9 (50) 9 (47) 10 (50)
Retransplantation [n (%)] 1 (6) 2 (10) 4 (20)
3 HLA mismatches [n (%)] 8 (44) 13 (68) 15 (75)
Positive PRA [n (%)] 1 (6) 2 (11) 4 (20)
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Table 2 Intra- and postoperative parameters. Groups are as follows: PROP (donor and recipient propofol), SEVO (donor and recipient sevo-
flurane), and PROSE (donor propofol and recipient sevoflurane). Data are given as the mean (SD), median (interquartile range), or n (%).
Continuous data were tested with ANOVA or the Kruskal–Wallis test (three groups) or Student’s unpaired t-test or the Mann–Whitney U-test
(two groups). Categorical data were analysed with Fisher’s exact test. BIS, bispectral index; BW, body weight; Cet, effect site concentration;
MAP, mean arterial pressure; PACU, postanaesthesia care unit; PaO2 , arterial partial pressure of oxygen; PONV, postoperative nausea and
vomiting. Warm ischaemia time 1 was defined as the time between division of the renal artery and cold perfusion with University of
Wisconsin solution; cold ischaemia time was defined as the total cold storage time; and warm ischaemia time 2 was defined as the time
between cold storage and recirculation (anastomosis time)
PROP SEVO PROSE P-value
Donor n518 n519 n520
Duration of procedure (min) 232 (32) 243 (41) 239 (33) 0.626
Perioperative fluid [ml (kg BW)1] 59.8 (12.3) 60.0 (11.1) 60.1 (11.3) 0.996
BIS 38 (7) 45 (6) 40 (4) 0.001
MAP (mm Hg) 87 (9) 75 (17) 85 (16) 0.066
Blood sample clip renal artery
pH 7.41 (0.03) 7.39 (0.04) 7.39 (0.04) 0.230
PaO2 (kPa) 19.1 (4.6) 19.8 (4.8) 19.0 (5.2) 0.876
Haemoglobin (mmol litre1) 7.3 (0.9) 7.3 (1.0) 7.1 (0.8) 0.628
Lactate (mmol litre1) 1.5 (0.4) 1.7 (0.7) 1.6 (0.7) 0.432
Medication
Propofol Cet 3.3 (0.5) — 3.1 (0.4) 0.301
Sevoflurane End tidal concentration — 1.53 (0.14) — —
Remifentanil Cet (ng ml1) 2.9 (0.9) 2.6 (0.8) 2.8 (1.0) 0.583
Vasoactive medication
Ephedrine [n (%)] 12 (67) 19 (100) 14 (70) 0.011
Dose (mg) 13 (6) 19 (11) 17 (8) 0.240
Phenylephrine [n (%)] 4 (22) 1 (5) 1 (5) 0.260
Dose (lg) 200 (125–200) 200 (100) 300 (300) 0.179
Piritramide
intraoperative (mg) 7.8 (1.3) 7.9 (1.1) 7.9 (1.2) 0.958
PACU (mg) 14.0 (10–18.5) 12.0 (9–21) 12.0 (9.3–14.8) 0.549
Ondansetron intraoperative [n (%)] 1 (6%) 8 (42%) 2 (10%) 0.015
PONV [n (%)]
PACU 5 (28) 4 (21) 9 (45) 0.270
Ondasetron 4 (22) 3 (16) 7 (35) 0.230
Dexamethasone 1 (6) 3 (16) 2 (10) 0.766
Droperidol 1 (6) 1 (5) 1 (5) 1.000
Recipient n518 n519 n520
Duration of procedure (min) 200 (29) 217 (33) 202 (27) 0.156
intraoperative fluid [ml (kg BW)1] 55.9 (13.0) 58.2 (17.8) 64.8 (9.6) 0.127
Average BIS 38 (7) 46 (7) 47 (4) <0.001
Average MAP (mm Hg) 92 (12) 83 (8) 80 (7) 0.001
Blood sample reperfusion
pH 7.38 (0.04) 7.37 (0.05) 7.37 (0.08) 0.657
PaO2 (kPa) 17.2 (5.8) 17.5 (4.4) 16.8 (5.6) 0.915
Haemoglobin (mmol litre1) 5.6 (5.1–6.3) 5.4 (4.8–6.1) 5.7 (4.9–6.0) 0.737
Lactate (mmol litre1) 1.4 (0.4) 1.7 (0.6) 1.6 (0.5) 0.305
Medication
Propofol Cet 3.3 (0.6) — — —
Sevoflurane End tidal concentration — 1.39 (0.27) 1.43 (0.18) 0.611
Remifentanil Cet (ng ml1) 3.3 (0.9) 2.4 (0.7) 2.5 (0.7) 0.001
Vasoactive medication bolus
Ephedrine [n (%)] 5 (28) 18 (95) 15 (75) <0.001
Dose (mg) 10 (7.5–10) 15 (10–25) 15 (10–30) 0.083
Phenylephrine [n (%)] 3 (17) 4 (21) 2 (10) 0.312
Dose (lg) 200 (200) 300 (100–1300) 225 (150–300) 0.815
Piritramide (mg)
intraoperative (mg) 8.0 (7.0–8.3) 7.0 (7.0–8.0) 7.0 (6.3–8.0) 0.259
PACU (mg) 15.4 (5.7) 15.9 (7.2) 15.5 (8.3) 0.975
Ondasetron perioperative [n (%)] 1 (6) 6 (32) 4 (20) 0.147
PONV [n (%)]
PACU 0 (0) 4 (21) 9 (45) 0.003
Ondasetron PACU 0 (0) 3 (16) 8 (40) 0.004
Dexamethasone PACU 0 (0) 1 (5) 2 (10) 0.310
Droperidol PACU 0 (0) 3 (16) 1 (5) 0.643
Ward 7 (39) 4 (21) 6 (30) 0.546
Kidney n518 n519 n520
Ischaemia time (min)
Warm ischaemia time 1 4 (3–4) 4 (3–4) 4 (3–5) 0.577
Cold ischaemia time 170 (35) 175 (47) 168 (28) 0.794
Warm ischaemia time 2 41 (7.5) 45 (8.2) 42 (6.0) 0.294
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specific antibodies were negative. Four rejections were cellular
(BANFF classification IA, PROP three and PROSE one) and five
vascular (BANFF classification IIa, PROP three and SEVO two).
Figure 3 shows Kaplan–Meier curves of the occurrence of acute rejec-
tion during 2 yr follow-up. There was a difference in death-censored
acute rejection between groups (P¼0.039). Post hoc testing revealed a
difference between PROP and PROSE (P¼0.020). The difference
between PROP and SEVO (11%) was not significant (P¼0.110).
Discussion
VAPOR-1 is the first randomized clinical trial to evaluate the
long-term effects of anaesthetic agents on biochemical and clin-
ical outcomes after LDKT. The main focus was the concen-
tration of three specific urinary renal injury markers reflecting
tubular damage as a result of IRI and preservation. Although we
hypothesized that sevoflurane-based anaesthesia would reduce
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Fig 2 Urinary concentrations of renal injury markers. Time points are as follows: first urine produced upon reperfusion, 2 h post-transplantation, day 1, 2, 6, and
9. Values are corrected for creatinine and displayed per group for every individual patient. Groups are as follows: PROP (donor and recipient propofol), SEVO
(donor and recipient sevoflurane), and PROSE (donor propofol and recipient sevoflurane). H-FABP, heart-type fatty acid binding protein; KIM-1, kidney injury mol-
ecule-1; NAG, N-acetyl-b-D-glucosaminidase. Differences were tested with the Kruskal–Wallis test and post hoc with the Bonferroni test.
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IRI, reflected by reduced concentrations of these markers, con-
centrations of KIM-1 and NAG showed unexpected patterns.
Kidney injury molecule-1, a type 1 cell membrane protein, is
not expressed in healthy individuals but is markedly upregu-
lated in chronic or acute kidney injury in proximal tubular cells,
turning these cells into phagocytes.14 Its ectodomain is cleaved
and shed in urine, where it remains highly stable. N-Acetyl-b-D-
glucosaminidase, a lysosomal enzyme in proximal tubular cells,
is rapidly released in urine upon injury. However, an increased
urinary activity of this enzyme might also reflect increased
lysosmal activity in renal tubular cells rather than damage to
these cells. Increased urinary NAG activity is also reported in a
variety of diseases, including hypertension.15 Clinical perform-
ance of these specific biomarkers is an area in evolution. When
this trial (2009–2010) was designed, little was known about the
performance of these biomarkers in a renal transplant setting.
One study by Zhang and colleagues,16 measuring the expression
of KIM-1 in renal transplant biopsies, showed that positive KIM-
1 staining identified proximal tubular injury and that its expres-
sion was correlated with the degree of renal dysfunction.
However, most studies testing the performance of these
markers were related to acute kidney injury (AKI). In this set-
ting, urinary KIM-1 and NAG have been shown to be sensitive
and early diagnostic indicators of renal injury. In discriminating
patients with AKI from healthy individuals, KIM-1 and NAG
showed an area under the receiver operating characteristic curve
of 0.95 and 1.00, respectively. In discriminating AKI from non-AKI
patients (intensive care unit patients, cardiac catheterization),
this was reduced to 0.93 and 0.83, respectively.17 However, the
prognostic performance of these biomarkers (and many others)
in predicting AKI varied greatly among studies, ranging from very
negative to very positive.18 We wanted to look at the entire tubu-
lar system; therefore, we have added H-FABP as a third bio-
marker. This cytoplasmatic protein involved in fatty acid
metabolism is the least renal specific of our markers and pre-
dominantly present in myocardial cells. In the kidney, it is
located in the distal tubular cells and released upon ischaemia.
In recent years, more research has been performed on the
role of urinary biomarkers and their ability to predict (long-
term) graft outcome in renal transplantation. Concentrations of
KIM-1 were measured in the urine of donors and recipients and
in machine perfusate of kidneys from living and deceased
donors.19–21 The results range from no prognostic performance
at all to poor prediction of DGF post-transplantation. In most of
these studies, KIM-1 is outperformed by other injury markers,
such as neutrophil gelatinase-associated lipocalin. It has been
suggested by several authors that increased KIM-1 concen-
trations might indicate on-going recovery and regeneration
after injury. This may lead to a paradigm shift in thinking about
biomarkers from substances released upon injury in which the
Table 3 Urinary concentrations of kidney injury markers after transplantation. Groups are as follows: PROP (donor and recipient propofol),
SEVO (donor and recipient sevoflurane), and PROSE (donor propofol and recipient sevoflurane). Data are given as the median (interquartile
range). Data were tested with the Kruskal–Wallis test and post hoc with the Bonferroni test. H-FABP, heart-type fatty acid binding protein;
KIM-1, kidney injury molecule-1; NAG, N-acetyl-b-D-glucosaminidase
PROP SEVO PROSE P-value
KIM-1 (pg mmol21) n518 n519 n520
0 h 149.6 (70.0–200.0) 123.6 (81.1–207.3) 144.3 (44.8–263.0) 0.961
2 h 28.7 (19.4–34.7) 29.6 (19.0–44.5) 33.5 (24.3–46.0) 0.311
Day 1 109.2 (71.6–165.5) 138.0 (80.1–289.0) 131.2 (73.7–238.6) 0.559




Day 6 238.1 (131.3–347.9) 311.2 (161.8–557.9) 252.4 (153.7–423.9) 0.960
Day 9 800.6 (604.4–1618.0) 1169.0 (421.1–2577.0) 886.4 (372.0–2381.0) 0.447
NAG (IU mmol21) n518 n519 n520
0 h 3.312 (2.378–4.256) 2.61 (1.968–4.140) 4.664 (1.953–7.304) 0.389
2 h 0.899 (0.579–1.057) 0.847 (0.522–0.947) 0.838 (0.630–1.019) 0.790








Day 6 1.217 (0.839–2.781) 1.991 (1.321–3.194) 1.612 (1.238–2.143) 0.309
Day 9 1.494 (0.873–2.578) 2.042 (1.286–4.016) 1.773 (1.229–2.983) 0.163
H-FABP (pg mmol21) n518 n519 n520
0 h 14 560 (9349–23 587) 12 924 (4137–18 610) 10 507 (4525–25 068) 0.433
2 h 2528 (1626–6483) 2854 (1217–6585) 4626 (2169–7878) 0.185
Day 1 1534 (864–2780) 1562 (703–3384) 2725 (1271–6117) 0.809
Day 2 838 (583–3216) 1144 (584–3043) 1063 (846–2736) 0.218
Day 9 372 (299–2539) 422 (267–1573) 470 (244–968) 0.889
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amount of biomarker is correlated with the amount of injury
(good predictor) to a more functional role of these substances in
healing and repair, making it a less strong or poor predictor of
outcome. In our study, concentrations of KIM-1, NAG, and H-
FABP in the first urine upon reperfusion were comparable
between groups. After this, H-FABP concentrations declined
during the post-transplant period and, in most patients, did not
increase again. In contrast, KIM-1 and NAG showed a different
pattern. After an initial decrease in KIM-1, concentrations in our
population increased again. On day 2, KIM-1 concentrations
were higher in SEVO compared with PROP. PROSE showed a ten-
dency to higher concentrations compared with PROP at this
time point. In vitro studies showed that shedding of the ectodo-
main of KIM-1 in urine is mediated by activation of ERK, and
this cleavage is accelerated by p38 MAPK activation.22
Interestingly, in proximal tubular cells, sevoflurane treatment
activates ERK and it provides neuroprotection by activation of
p38 MAPK 24–72 h after reperfusion in the rat brain.23 24
As stated above, evidence is accumulating that AKI KIM-1
may play an important role in the regeneration and repair proc-
ess. Recently, Yang and colleagues25 are able to phagocytize
luminal cellular debris consisting of apoptotic and necrotic cells,
enabling the proximal tubular cell to downregulate the innate
immune response upon AKI. This could be beneficial in kidney
transplantation because an inflammatory environment
attributable to parenchymal injury during transplantation
makes the graft more prone to acute and chronic rejection.26 27
Furthermore, in renal transplant recipients with AKI, Zhang and
colleagues16 showed that higher concentrations of KIM-1
expression were associated with a better recovery over time. In
our study, the second increase at day 9 in all groups could be
explained by calcineurin inhibitor nephrotoxicity.28 29
Regarding NAG in our study, the highest NAG activity was
observed in the first urine produced. This is probably a true
reflection of the IRI and preservation process. After a decrease
Table 4 Clinical outcomes in recipients. Groups are as follows: PROP (donor and recipient propofol), SEVO (donor and recipient sevoflur-
ane), and PROSE (donor propofol and recipient sevoflurane). Data are given as the median (interquartile range) or n (%). mGFR, measured
glomerular filtration rate measured with 125I-iothalamate; mGFR was tested with linear mixed models, with autoregression correlation
between repeated measurements. Continuous data were analysed with the Kruskal–Wallis test. Categorical data were analysed with
Fisher’s exact test. Acute rejection episodes were tested with the log-rank test
PROP SEVO PROSE P-value
Renal function n518 n519 n520
Urinary splint output during first 2 h (ml)
First hour 325 (150–350) 275 (170–350) 303 (156–350) 0.868
Second hour 350 (194–644) 350 (145–500) 275 (175–444) 0.492
mGFR (ml min1)
3 months 64 (51–68) (n¼13) 66 (56–76) (n¼17) 60 (49–71) (n¼19) 0.505
6 months 61 (50–71) (n¼16) 68 (57–78) (n¼18) 56 (47–71) (n¼17)
1 yr 57 (48–65) (n¼19) 59 (46–67) (n¼19) 54 (44–67) (n¼19)
Delayed graft function [n (%)] 2 (11) 1 (5) 0 (0) 0.199
Primary non-function [n (%)] 0 (0) 0 (0) 0 (0) 1.000
n¼17 n¼19 n¼20
Graft loss [n (%)] 1 (6) 1 (5) 0 (0) 0.536
Acute rejection 2 yr [n (%)] 6/17 (35) 2/19 (11) 1/20 (5) 0.039
Postoperative course
Complications Clavien–Dindo
Grade I 5 4 5 0.928
Grade II 3 3 3 0.670
Grade IIIa 2 0 0 0.096
Grade III 1 2 2 1.000
Grade IVa 0 0 0 1.000
Grade IV 0 0 0 1.000
Grade V 1 0 0 0.316
Hospital stay (days) 17 (17–18.25) 17 (17–17) 17 (17–17) 0.457
1.0
PROSE n=20
SEVO    n=19
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Fig 3 Kaplan–Meier curves of the occurrence of acute rejection during 2 yr
follow-up. The rejection-free fraction is displayed on the y-axis. Groups
are as follows: PROP (donor and recipient propofol), SEVO (donor and
recipient sevoflurane), and PROSE (donor propofol and recipient sevoflur-
ane). Acute rejection episodes were tested with the log-rank test.
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in activity over the first day, it increased again on day 2 after
transplantation and generally remained stable on days 6 and 9.
On day 2, SEVO showed higher concentrations compared with
PROP. This could be a reflection of regenerated tubular cells
showing baseline lysosomal activity. Kotanko and colleagues30
showed that a low urinary NAG activity between week 2 and 4
post-transplantation is associated with poorer graft survival after
4 yr compared with high urinary NAG activity during this period.
Overall, our results can be interpreted two ways: the second
increase of the biomarkers KIM-1 and NAG could be attributable
to injury or (in our opinion, more likely) it could be associated
with increased regeneration and recovery of the tubular system.
Higher concentrations were not associated with inferior graft out-
come. Concentrations of KIM-1 and NAG on day 2 were strongly
correlated (P<0.001), and the correlation of estimated glomurelar
filtration rate (eGFR) at 1 month and KIM-1 concentrations at day
2 wass almost significant (P¼0.074), where a higher KIM-1
concentration was correlated with a higher eGFR.
Expression of HO-1 in cold biopsies was higher in kidneys
exposed to sevoflurane compared with kidneys exposed to propo-
fol. Sevoflurane-induced upregulation of HO-1 has been described
in different cell types.31 32 Organ protection via the HO-1 pathway
is probably one of the pathways involved in anaesthetic condi-
tioning with VA. However, in reperfusion biopsies this difference
was no longer visible. This can be explained by the fact that upon
injury most cell types upregulate HO-1 as a mechanism of self-
protection. This was also reflected in the extensive upregulation
of hsp-70 in all groups upon reperfusion.
Pathology scores did not differ between groups. This could
be because of the fact that our protocol biopsies were obtained
30 min after reperfusion at skin closure. In the literature, dif-
ferences are found only 3 h post-reperfusion.5
This study has several limitations. The LDKT setting pro-
vided an optimal research setting but also had substantial draw-
backs. We did expect that, although the amount of injury in this
setting is lower compared with injury in kidneys from deceased
donors, cytokines reflecting IRI would be measurable in plasma.
But to our surprise, many of these cytokines were below the
detection threshold. Many factors influence conditioning strat-
egies, including patients’ co-morbidity and use of medication.
We have looked at these factors, and the groups are comparable.
However, we cannot exclude the possibility that co-morbidity or
medication might have played a role in the success or failure of
our conditioning strategies. Some minor, although statistically
significant, differences between groups regarding intraoperative
care were observed. Ephedrine, mostly administered after
induction of anaesthesia, was given more frequently in patients
anaesthetized with sevoflurane. In these patients, anaesthesia
was induced with a manually administered bolus of propofol,
which might induce larger cardiovascular changes compared
with the target-controlled infusion-administered propofol in
the propofol-based anaesthesia. Profound hypotension over
extended periods was not observed, and continuous vasopressic
support was not required. Although the MAP during the proce-
dure was lower in recipients anaesthetized with sevoflurane, it
was still >80% of the patients’ baseline range. To stay within
this range, remifentanil Cet was adjusted, resulting in a lower
Cet in recipients anaesthetized with sevoflurane. Protection
against IRI with the use of remifantanil has been described for
several organs in animal experiments. Most of these studies
used a conditioning strategy of two or three times a cycle of
5 min remifentanil infusion followed by 5 min of reperfusion.
The doses used in these experiments are rather high (heart,
6.0 lg kg1 min1) compared with the continuous dose we used
in our clinical setting (range 0.08–0.12 lg kg1 min1).33 One
study using lower doses (0.1–1lg kg1 min1) for precondition-
ing of the intestine reported a dose-independent effect.34
Studies using continuous or semi-continuous infusion during
the entire procedure or before and during the ischaemic period
show a dose-independent effect in the liver (dose ranging from
0.4 to 10.0 lg kg1 min1), but in the brain a protective effect was
seen only in the high range dose (1.8 lg kg1 min1).35 36 In our
opinion, the difference in Cet between our groups does not have
any clinical significance or any effect on conditioning. The lower
Cet of remifentanil might also result in greater arousability,
leading to a higher overall BIS value in SEVO and PROSE.
However, the overall depth and stability of anaesthesia can be
considered clinically similar among groups without inducing
effects on the study objectives. Volatile anaesthetics are a
known cause of PONV. Therefore, the increased use of ondanse-
tron for PONV in sevoflurane groups was anticipated.
To our surprise, we observed a significant difference in the
occurrence of T-cell-mediated rejection between groups during the
first 2 yr after transplantation in favour of the sevoflurane groups.
As there were only nine events, we could not perform an adequate
multivariate analysis. However, known risk factors, such as human
leucocyte antigen mismatches, panel specific antibodies>15%, and
second or third transplantation, had a higher incidence in SEVO
and PROSE. It has been shown that both anaesthetic agents have
differential effects on cells of the immune system. Several studies
have shown the inhibitory effects of VA on lymphocyte prolifera-
tion and cytokine release and the ability of VA to induce apoptosis
in T lymphocytes. Propofol has a minor effect on lymphocyte prolif-
eration and function.37 It has also been shown in vitro that both pro-
pofol and sevoflurane blockage Lymphocyte function-associated
antigen 1 (LFA-1) at the lovastatin binding site.38 39 Blockage of
LFA-1 is recognized as a potential target to reduce allograft re-
jection, through effects on T-cell migration and antigen pre-
sentation.40 41 Although both anaesthetics possess this ability
in vitro, we do not know whether this effect is comparable in vivo.
Unfortunately, we did not collect cells and were unable to look at
the effects of both agents on cell subtypes.
As the next step, we will proceed with VAPOR-2, a multicentre
randomized controlled trial comparing sevoflurane-based anaes-
thesia vs propofol-based anaesthesia on clinical renal outcome
(DGF) in kidney transplantation with kidneys of deceased donors.
In conclusion, in LDKT sevoflurane- or propofol-based
anaesthesia resulted in comparable concentrations of urinary
renal biomarkers in the first urine produced upon reperfusion.
On day 2, sevoflurane-based anaesthesia led to higher urinary
concentrations of KIM-1 and NAG but not H-FABP. These higher
concentrations were not associated with inferior graft outcome.
Remarkably, a lower acute rejection rate after 2 yr was seen in
recipients receiving sevoflurane.
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